Munir Asma, Holt Simon, Huws Anita Marie, Khan Sohail, Davies Dr Mark, Khawaja Saira, Sharaiha Yousef
Dept. of Breast Surgery, Prince Philip Hospital, United Kingdom.
Dept. of Breast Surgery, Prince Philip Hospital, United Kingdom.
Cancer Treat Res Commun. 2023;34:100671. doi: 10.1016/j.ctarc.2022.100671. Epub 2022 Dec 11.
To explore the long-term outcome of patients who underwent Oncotype DX® testing. The relationship between the RS, adjuvant treatments received, and clinical outcomes across the entire range of RS results are reported.
10-year Kaplan-Meier estimates for distant recurrence/BC-specific survival (BCSS) in this cohort. The analysis included 439 patients. The follow-up time ranged from 14 to 142 months. All analyses were performed using the SPSS v20.
More than half of patients had low RS (<18) (55.6%) and 15.3% had RS ≥ 31. Chemotherapy use was consistent with the RS with 4.4%, 7.1%, 28.0%, 71.4% and 91.0% receiving adjuvant chemotherapy in patients with RS < 11, 11-17, 18-25, 26-30, and ≥31, respectively. The overall chemotherapy rate was 27.6%. Distant metastasis free survival (DMFS) differed significantly (P < 0.001) between the RS groups with 10 year DMFS rates of 99% (SE +/- 0.01) in the RS<11, 97% (SE +/- 0.03) in the RS 11-17, 97% (SE +/- 0.02) in the RS 18-25, 85% (SE +/- 0.1) in the RS 26-30 and 74% (SE +/- 0.08) in the RS ≥ 31 group. Ten year breast cancer specific survival also differed significantly (P < 0.001) between the RS groups; this risk was 100% (no deaths from breast cancer reported in the first 10 years) in RS < 11, 95% (SE +/- 0.03) in RS 11-17, 94% (SE +/- 0.04) in RS 18-25, 93% (SE +/- 0.07) in RS 26-30, and 79% (SE +/- 0.07) in the RS ≥ 31 group.
Use of Oncotype DX RS does guide the treatment decisions and correlates with the BCSS and disease-free survival for ER positive, Her2 negative, early-stage, node negative breast cancer patients.
探讨接受Oncotype DX®检测的患者的长期预后。报告了复发评分（RS）、接受的辅助治疗与整个RS结果范围内临床结局之间的关系。
对该队列中远处复发/乳腺癌特异性生存（BCSS）的10年Kaplan-Meier估计值进行分析。该分析纳入了439例患者。随访时间为14至142个月。所有分析均使用SPSS v20进行。
超过一半的患者RS较低（<18）（55.6%），15.3%的患者RS≥31。化疗的使用与RS一致，RS<11、11-17、18-25、26-30和≥31的患者接受辅助化疗的比例分别为4.4%、7.1%、28.0%、71.4%和91.0%。总体化疗率为27.6%。RS组之间的无远处转移生存期（DMFS）有显著差异（P<0.001），RS<11组的10年DMFS率为99%（标准误±0.01），RS 11-17组为97%（标准误±0.03），RS 18-25组为97%（标准误±0.02），RS 26-30组为85%（标准误±0.1），RS≥31组为74%（标准误±0.08）。RS组之间的10年乳腺癌特异性生存率也有显著差异（P<0.001）；RS<11组的该风险为100%（前10年无乳腺癌死亡报告），RS 11-17组为95%（标准误±0.03），RS 18-25组为94%（标准误±0.04），RS 26-30组为93%（标准误±0.07），RS≥31组为79%（标准误±0.07）。
Oncotype DX复发评分的使用确实指导了治疗决策，并与雌激素受体阳性、人表皮生长因子受体2阴性、早期、无淋巴结转移的乳腺癌患者的乳腺癌特异性生存和无病生存期相关。
